BACKGROUND: Adipocytokines may mediate the association between adiposity and lethal prostate cancer outcomes. METHODS: In the Physicians' Health Study, we prospectively examined the association of prediagnostic plasma concentrations of adiponectin and leptin with risk of developing incident prostate cancer (654 cases diagnosed 1982-2000 and 644 age-matched controls) and, among cases, risk of dying from prostate cancer by 2007. RESULTS: Adiponectin concentrations were not associated with risk of overall prostate cancer. However, men with higher adiponectin concentrations had lower risk of developing high-grade or lethal cancer (metastatic or fatal disease). The relative risk (95% CI) comparing the highest quintile to the lowest (Q5 vs Q1) was 0.25 (95% CI 0.07-0.87; P(trend) = 0.02) for lethal cancer. Among all the cases, higher adiponectin concentrations predicted lower prostate cancer-specific mortality [hazard ratio (HR)(Q5 vs Q1)= 0.39; 95% CI 0.17-0.85; P(trend) = 0.02], independent of body mass index (BMI), plasma C-peptide (a marker of insulin secretion), leptin, clinical stage, and tumor grade. This inverse association was apparent mainly among men with a BMI >or=25 kg/m(2) (HR(Q5 vs Q1)= 0.10; 95% CI 0.01-0.78; P(trend) = 0.02), but not among men of normal weight (P(trend) = 0.51). Although the correlation of leptin concentrations with BMI (r = 0.58, P < 0.001) was stronger than that of adiponectin (r = -0.17, P < 0.001), leptin was unrelated to prostate cancer risk or mortality. CONCLUSIONS: Higher prediagnostic adiponectin (but not leptin) concentrations predispose men to a lower risk of developing high-grade prostate cancer and a lower risk of subsequently dying from the cancer, suggesting a mechanistic link between obesity and poor prostate cancer outcome.
BACKGROUND: Adipocytokines may mediate the association between adiposity and lethal prostate cancer outcomes. METHODS: In the Physicians' Health Study, we prospectively examined the association of prediagnostic plasma concentrations of adiponectin and leptin with risk of developing incident prostate cancer (654 cases diagnosed 1982-2000 and 644 age-matched controls) and, among cases, risk of dying from prostate cancer by 2007. RESULTS:Adiponectin concentrations were not associated with risk of overall prostate cancer. However, men with higher adiponectin concentrations had lower risk of developing high-grade or lethal cancer (metastatic or fatal disease). The relative risk (95% CI) comparing the highest quintile to the lowest (Q5 vs Q1) was 0.25 (95% CI 0.07-0.87; P(trend) = 0.02) for lethal cancer. Among all the cases, higher adiponectin concentrations predicted lower prostate cancer-specific mortality [hazard ratio (HR)(Q5 vs Q1)= 0.39; 95% CI 0.17-0.85; P(trend) = 0.02], independent of body mass index (BMI), plasma C-peptide (a marker of insulin secretion), leptin, clinical stage, and tumor grade. This inverse association was apparent mainly among men with a BMI >or=25 kg/m(2) (HR(Q5 vs Q1)= 0.10; 95% CI 0.01-0.78; P(trend) = 0.02), but not among men of normal weight (P(trend) = 0.51). Although the correlation of leptin concentrations with BMI (r = 0.58, P < 0.001) was stronger than that of adiponectin (r = -0.17, P < 0.001), leptin was unrelated to prostate cancer risk or mortality. CONCLUSIONS: Higher prediagnostic adiponectin (but not leptin) concentrations predispose men to a lower risk of developing high-grade prostate cancer and a lower risk of subsequently dying from the cancer, suggesting a mechanistic link between obesity and poor prostate cancer outcome.
Authors: T Yokota; K Oritani; I Takahashi; J Ishikawa; A Matsuyama; N Ouchi; S Kihara; T Funahashi; A J Tenner; Y Tomiyama; Y Matsuzawa Journal: Blood Date: 2000-09-01 Impact factor: 22.113
Authors: Susan A Phillips; Theodore P Ciaraldi; Alice P S Kong; Rahil Bandukwala; Vanita Aroda; Leslie Carter; Sunita Baxi; Sunder R Mudaliar; Robert R Henry Journal: Diabetes Date: 2003-03 Impact factor: 9.461
Authors: Joseph G Yu; Sandrine Javorschi; Andrea L Hevener; Yolanta T Kruszynska; Rodney A Norman; Madhur Sinha; Jerrold M Olefsky Journal: Diabetes Date: 2002-10 Impact factor: 9.461
Authors: T Yamauchi; J Kamon; H Waki; Y Terauchi; N Kubota; K Hara; Y Mori; T Ide; K Murakami; N Tsuboyama-Kasaoka; O Ezaki; Y Akanuma; O Gavrilova; C Vinson; M L Reitman; H Kagechika; K Shudo; M Yoda; Y Nakano; K Tobe; R Nagai; S Kimura; M Tomita; P Froguel; T Kadowaki Journal: Nat Med Date: 2001-08 Impact factor: 53.440
Authors: T Yamauchi; J Kamon; Y Minokoshi; Y Ito; H Waki; S Uchida; S Yamashita; M Noda; S Kita; K Ueki; K Eto; Y Akanuma; P Froguel; F Foufelle; P Ferre; D Carling; S Kimura; R Nagai; B B Kahn; T Kadowaki Journal: Nat Med Date: 2002-10-07 Impact factor: 53.440
Authors: Barbra A Dickerman; Johanna E Torfadottir; Unnur A Valdimarsdottir; Edward Giovannucci; Kathryn M Wilson; Thor Aspelund; Laufey Tryggvadottir; Lara G Sigurdardottir; Tamara B Harris; Lenore J Launer; Vilmundur Gudnason; Sarah C Markt; Lorelei A Mucci Journal: Cancer Date: 2019-06-10 Impact factor: 6.860
Authors: Paul L Nguyen; Jing Ma; Jorge E Chavarro; Matthew L Freedman; Rosina Lis; Giuseppe Fedele; Christopher Fiore; Weiliang Qiu; Michelangelo Fiorentino; Stephen Finn; Kathryn L Penney; Anna Eisenstein; Fredrick R Schumacher; Lorelei A Mucci; Meir J Stampfer; Edward Giovannucci; Massimo Loda Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger Journal: Cancer Prev Res (Phila) Date: 2012-10-03
Authors: Katharine N Sourbeer; Lauren E Howard; Gerald L Andriole; Daniel M Moreira; Ramiro Castro-Santamaria; Stephen J Freedland; Adriana C Vidal Journal: BJU Int Date: 2014-10-20 Impact factor: 5.588
Authors: Stacey A Kenfield; Julie L Batista; Jaquelyn L Jahn; Mary Kathryn Downer; Erin L Van Blarigan; Howard D Sesso; Edward L Giovannucci; Meir J Stampfer; June M Chan Journal: J Natl Cancer Inst Date: 2015-11-17 Impact factor: 13.506